NCT03161379 - GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 2, 2018

Primary Completion Date

February 20, 2024

Study Completion Date

February 28, 2024

Conditions

Pancreatic Cancer

Interventions

DRUG

Cyclophosphamide

Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.

DRUG

Nivolumab

Nivolumab (240 mg) will be administered one day prior to vaccination. First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.

DRUG

GVAX Pancreas Vaccine

Vaccine will be administered one day after cyclophosphamide and nivolumab. 3 weeks after the first dose of immunotherapy the second dose will be given.

RADIATION

Stereotactic Body Radiation (SBRT)

SBRT (6.6 Gy over 5 days) will be started during the second dose of immunotherapy (3 weeks after the first dose of immunotherapy).

Trial Locations (2)

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

53226

Medical College of Wisconsin, Milwaukee